Drug Product Pipeline Portal (Member View)
The AMCP Drug Product Pipeline is the latest innovation in providing access and insight into the formulary decision-making process. Designed to alleviate the workloads of pharmacy benefit managers and health care decision makers, the Pipeline aggregates data from government databases as well as other publicly available sources to provide a one-stop portal featuring the next generation of pharmaceuticals.
AMCP, in partnership with Apperture, created the Pipeline to provide users with insight into the latest pharmaceuticals that will impact their managed care practice and patients' health over the next five years.
Use the buttons below to toggle between Non-Oncology, Oncology, and FDA Expedited Programs dashboards.
How to use these dashboards.
How to Use
Tips for using the AMCP Drug Product Pipeline Tracker (Member View):
- Use the search boxes to filter data by specific conditions.
- Select parts of any of the charts/tables to further filter the data.
- More than one value for a chart filter can be selected by pressing down the
- "Ctrl" button.
- The Related Studies table provides links to the specific clinical trial on the clinicaltrials.gov page.
- Use the "reset" button in the bottom grey ribbon of the dashboard to revert to the default view.
ClinicalTrials.gov data was extracted for Phase II, Phase II/III, and Phase III clinical trials.
Data was cleaned using Apperture pre-specified rules detailed below.
- Inclusion:
- Trials reading out between 2016 and 2026 were included.
- Trials with active, completed, enrolling, not yet recruiting, and recruiting status were included.
- Only trials with FDA-regulated drugs were included.
- Exclusion:
- Trials with a suspended, terminated, withdrawn, or missing status were excluded.
- Trials with oncological conditions were excluded.
- Therapies and trials of therapies with previously approved FDA indications were excluded.
- Analysis and reporting:
- Routes of administration were coded, and conditions were mapped to therapeutic areas.
- Data validation was conducted at each step in the process.
- Data were analyzed using Microsoft Access and Excel and dashboards created in Tableau.
ClinicalTrials.gov data was extracted for Phase II, Phase II/III, and Phase III clinical trials.
Data was cleaned using Apperture pre-specified rules detailed below.
- Inclusion:
- Trials reading out between 2016 and 2026 were included.
- Trials with active, completed, enrolling, not yet recruiting. and recruiting status were included.
- Trials with FDA-regulated drugs were included.
- Trials with oncological conditions were selected even if the therapy was FDA-approved or licensed.
- Exclusion:
- Trials with a suspended, terminated, withdrawn, or missing status were excluded.
- Analysis and reporting:
- Routes of administration were coded, and conditions were mapped to therapeutic areas.
- Data validation was conducted at each step in the process.
- Data were analyzed using Microsoft Access and Excel and dashboards created in Tableau.
- FDA Expedited Programs data files were downloaded from quarterly reports available at https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program and https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/nda-and-bla-approvals.
- ClinicalTrials.gov data was extracted for all the therapies that have received, Breakthrough Therapy Designation (BD), Orphan Drug Designation (OD), Priority Review designation (PR), or Accelerated Approval (AA).
- Expedited review programs are not mutually exclusive (e.g., products may receive both priority review and breakthrough designation). In addition, products may have orphan drug designation for multiple indications.
- Only those products with a check mark received the corresponding designation or accelerated approval.
Limitations
- ClinicalTrials.gov is updated daily and completeness of the data is impacted by reporting delays, quality of data entry, and business decisions.
- Variations in ClinicalTrials.gov data entry may result in multiple drug entries or condition/indications.
Data Sources: Primary data source is Clinicaltrials.gov supplemented by publicly available data including manufacturer websites.
Last Clinicaltrials.gov data update: Sept. 30, 2022
